Sanavia Oncology Inc.
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Oncology
In drug development, the epitope matters. Current therapies targeting known epitopes can only help 20% of cancer patients. Sanavia Oncology Inc. is a Series B stage New York-based biotech company focusing on finding and targeting the right epitope by ADCs in the remaining 80% of patients.
What drives us at Sanavia is not just the technology—we're driven by impact. By combining a unique approach to epitope discovery, high-throughput functional antibody screening and AI-driven structure prediction, we generate structurally and functionally optimized antibody drug candidates that target the right epitope with the right geometry for improved safety and efficacy, significantly expanding the number of patients who can benefit. Our SANA-01 ADC safely targets a novel cancer-specific epitope that’s present in a high percentage of patients across major cancers, including up to 75% of lung, 70% of TNBC, 70% of ovarian, 40% of colon, 75% of pancreatic, and 55% of gastric cancers.
Company HQ City:
New York
Company HQ State:
NY
Company HQ Country:
United States
Year Founded:
2021
Lead Product in Development:
SANA-01 ADC
CEO
Server Ertem
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
June 2027
What is your next catalyst (value inflection) update?
IND application for SANA-01
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}